Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I, First in Human Study of CBA-1205, Anti-DLK1 Monoclonal Antibody in Patients with Advanced Solid Tumors and Hepatocellular Carcinoma (HCC)

Next Previous
Trial Profile

A Phase I, First in Human Study of CBA-1205, Anti-DLK1 Monoclonal Antibody in Patients with Advanced Solid Tumors and Hepatocellular Carcinoma (HCC)

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 24 Feb 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs CBA 1205 (Primary)
  • Indications Carcinoma; Liver cancer; Malignant melanoma; Solid tumours
  • Focus Adverse reactions; First in man
  • Sponsors Chiome Bioscience

Most Recent Events

  • 21 Jan 2025 According to a Chiome Bioscience media release, the company announced that results(n=22) evaluating safety and efficacy of the CBA-1205 from the first part of this study were published in an international academic journal, Cancer Science.
  • 14 Dec 2023 According to a Chiome Bioscience media release, company announced first half of this clinical trial of CBA-1205 in patients with solid tumours was conducted at the National Cancer Centre. Second part of the trial is being conducted in patients with hepatocellular carcinoma.
  • 11 May 2023 According to a Chiome Bioscience media release, the second part of the Phase I study is ongoing.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top